Max Colao
Equibles does not estimate personal net worth.
About Max Colao
Aurinia Pharmaceuticals Inc. reported in an 8-K filed July 15, 2022 that Max Colao was terminated as Chief Commercial Officer, effective July 22, 2022. The proxy statement of Aurinia Pharmaceuticals Inc. reports total compensation of $3,603,002 for Max Colao in fiscal 2022, including a base salary of $274,970. Disclosed compensation is on record for 5 fiscal years. Max Colao has spoken on 1 earnings call across 1 company, most recently for Aurinia Pharmaceuticals Inc. on May 6, 2021. The companies whose calls Max Colao spoke on are classified in the Healthcare sector.
“On July 11, 2022, Aurinia Pharmaceuticals Inc. and Max Colao, our Chief Commercial Officer, mutually agreed that Mr. Colao would cease his employment with Aurinia, effective July 22, 2022.”
Max Colao on recent calls
“Let me begin with the three takeaways that I learned from my remarks. Then I will provide some supporting details and key points. First, as Peter highlighted, I am pleased to report that our progress and results in the first quarter are in line with our expectations.”
Affiliation history
-
Aurinia Pharmaceuticals Inc. (AUPH)
Proxy statement
Start not stated–2022-07-22
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Aurinia Pharmaceuticals Inc. (AUPH) | Former Chief Commercial Officer | $274,970 | $3,603,002 |
| 2021 | Aurinia Pharmaceuticals Inc. (AUPH) | Former Chief Commercial Officer | $459,000 | $710,157 |
| 2020 | Aurinia Pharmaceuticals Inc. (AUPH) | Former Chief Commercial Officer | $354,167 | $4,845,900 |
| 2019 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Commercial Officer | — | — |
| 2018 | Aurinia Pharmaceuticals Inc. (AUPH) | Chief Commercial Officer | — | — |